The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway

Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of c...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 21; no. 1; pp. 1 - 20
Main Authors Zhang, Yi, Liu, Xiaomeng, Wang, Yan, Lai, Shihui, Wang, Zhiqian, Yang, Yudie, Liu, Wenhui, Wang, Hongquan, Tang, Bo
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 02.09.2022
BioMed Central
BMC
Subjects
ALKBH5
Animal models
Antibodies
Binding sites
Bioinformatics
Cancer
Care and treatment
Chemoresistance
Chemosensitivity
Chemotherapy
DDIT4-AS1
DNA damage
Drug resistance
Flow cytometry
Gemcitabine
Growth factors
HuR protein
Hypoxia
Immunoprecipitation
Medical prognosis
Methyltransferases
Molecular modelling
mRNA stability
N6-methyladenosine
Pancreatic cancer
Patients
Phosphorylation
Prognosis
Proteins
RNA
RNA sequencing
Scientific equipment and supplies industry
Stemness
TOR protein
Tumors
UPF1
Xenografts
United States
China
Grand Island New York
St Louis Missouri
United States > US
Germany
Online AccessGet full text

Cover

Abstract Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated. Methods m.sup.6A-RNA immunoprecipitation and sequencing were used to screen m.sup.6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM. Results DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m.sup.6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC. Conclusions The ALKBH5-mediated m.sup.6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC. Keywords: ALKBH5, Stemness, Chemosensitivity, DDIT4-AS1, UPF1
AbstractList Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated. m.sup.6A-RNA immunoprecipitation and sequencing were used to screen m.sup.6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM. DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m.sup.6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC. The ALKBH5-mediated m.sup.6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC.
Abstract Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated. Methods m6A-RNA immunoprecipitation and sequencing were used to screen m6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM. Results DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC. Conclusions The ALKBH5-mediated m6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC.
Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated. Methods m6A-RNA immunoprecipitation and sequencing were used to screen m6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM. Results DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC. Conclusions The ALKBH5-mediated m6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC.
Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated. Methods m.sup.6A-RNA immunoprecipitation and sequencing were used to screen m.sup.6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM. Results DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m.sup.6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC. Conclusions The ALKBH5-mediated m.sup.6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC. Keywords: ALKBH5, Stemness, Chemosensitivity, DDIT4-AS1, UPF1
Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated.BACKGROUNDChemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated.m6A-RNA immunoprecipitation and sequencing were used to screen m6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM.METHODSm6A-RNA immunoprecipitation and sequencing were used to screen m6A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM.DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC.RESULTSDDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m6A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC.The ALKBH5-mediated m6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC.CONCLUSIONSThe ALKBH5-mediated m6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemoresistance in PDAC.
ArticleNumber 174
Audience Academic
Author Wang, Hongquan
Lai, Shihui
Tang, Bo
Liu, Wenhui
Zhang, Yi
Liu, Xiaomeng
Wang, Yan
Wang, Zhiqian
Yang, Yudie
Author_xml – sequence: 1
  givenname: Yi
  surname: Zhang
  fullname: Zhang, Yi
– sequence: 2
  givenname: Xiaomeng
  surname: Liu
  fullname: Liu, Xiaomeng
– sequence: 3
  givenname: Yan
  surname: Wang
  fullname: Wang, Yan
– sequence: 4
  givenname: Shihui
  surname: Lai
  fullname: Lai, Shihui
– sequence: 5
  givenname: Zhiqian
  surname: Wang
  fullname: Wang, Zhiqian
– sequence: 6
  givenname: Yudie
  surname: Yang
  fullname: Yang, Yudie
– sequence: 7
  givenname: Wenhui
  surname: Liu
  fullname: Liu, Wenhui
– sequence: 8
  givenname: Hongquan
  surname: Wang
  fullname: Wang, Hongquan
– sequence: 9
  givenname: Bo
  surname: Tang
  fullname: Tang, Bo
BookMark eNp9kt9u0zAUxiM0xP7AC3BliRtuMuzEjp0bpLIBq5g0Ccq15TgnravELrGzqY_Dm3LaThOdEIqiHNnf93PO8XeenfjgIcveMnrJmKo-RFbUvMxpUeSUVVzm9EV2xrisci5qdfJXfZqdx7imlEkl-avstKyoqEohzrLfixWQoZqRFgZIq21vIpDZ7bdPNyIfoHUmQUumzQjLqTfJBU9CR66v5wuez34wMhjnE76RbIy3I6DEEosljCQmGDzESIxvSZw2CIkRIrErGEIEH11y9y5tSbMlxmKNZr8kafdDi7vvSEyrB7N9nb3sTB_hzeP3Ivv55fPi6ia_vfs6v5rd5pZLmvLWMiU4qFZKwQTtasYpt5R3jVKNpBWrCiOgrEUNQCuoqVBdWzMFhnFRWlFeZPMDtw1mrTejG8y41cE4vV8I41KbEdvrQcuCm6Lp2rIrJW-EMVzaijPVguq4AYusjwfWZmpwihZ8Gk1_BD3e8W6ll-Fe430qJiQC3j8CxvBrgpj04KKFvjcewhR1IWkty4rTAqXvnknXYRo9jgpVTAipFFKfVEuDDTjfBTzX7qB6JllFS5wCRdXlP1T4YDqcxfR1DtePDMXBYMcQ4wjdU4-M6l1I9SGkGkOq9yHVO5N6ZrIu7cOFp7n-f9Y_513seQ
CitedBy_id crossref_primary_10_1016_j_bbrep_2023_101600
crossref_primary_10_1038_s41467_023_36747_y
crossref_primary_10_1016_j_pharmthera_2024_108671
crossref_primary_10_3389_fimmu_2022_995645
crossref_primary_10_1016_j_prp_2025_155837
crossref_primary_10_1186_s40001_024_02033_w
crossref_primary_10_1038_s12276_024_01158_6
crossref_primary_10_3390_polym16172418
crossref_primary_10_1016_j_phrs_2024_107280
crossref_primary_10_1007_s10142_023_01277_9
crossref_primary_10_1038_s41598_024_59464_y
crossref_primary_10_3389_fonc_2023_1290330
crossref_primary_10_1021_acs_est_4c08669
crossref_primary_10_1186_s12935_024_03480_5
crossref_primary_10_3389_fendo_2023_1110624
crossref_primary_10_1007_s00432_024_05824_0
crossref_primary_10_1007_s11010_024_05040_x
crossref_primary_10_1016_j_ncrna_2024_06_002
crossref_primary_10_1186_s13578_024_01286_6
crossref_primary_10_1016_j_ygeno_2023_110594
crossref_primary_10_1021_acsomega_2c07280
crossref_primary_10_1186_s11658_024_00611_8
crossref_primary_10_1111_cas_16380
crossref_primary_10_1155_jfbc_8272754
crossref_primary_10_1016_j_gene_2023_148007
crossref_primary_10_3390_ijms24031828
crossref_primary_10_1002_advs_202207257
crossref_primary_10_1159_000533421
crossref_primary_10_1016_j_heliyon_2023_e20969
crossref_primary_10_1016_j_prp_2023_154438
crossref_primary_10_1158_1541_7786_MCR_23_0720
crossref_primary_10_1186_s40246_024_00693_7
crossref_primary_10_1016_j_jhazmat_2024_134790
crossref_primary_10_1016_j_biopha_2024_116479
crossref_primary_10_1186_s12885_024_13146_0
crossref_primary_10_1186_s12935_023_02955_1
crossref_primary_10_3892_ijmm_2024_5463
crossref_primary_10_1016_j_intimp_2024_112050
crossref_primary_10_1007_s12094_022_03060_x
crossref_primary_10_1016_j_cej_2025_160854
crossref_primary_10_1186_s12943_024_02089_6
crossref_primary_10_1002_mc_23668
crossref_primary_10_1016_j_molcel_2023_05_010
crossref_primary_10_1038_s41576_024_00723_z
crossref_primary_10_1038_s41419_024_07148_w
crossref_primary_10_1186_s40001_023_01388_w
crossref_primary_10_1186_s12943_022_01680_z
crossref_primary_10_3389_fddsv_2024_1465222
Cites_doi 10.1016/j.stem.2020.04.009
10.1016/j.phymed.2020.153191
10.1101/gad.1617608
10.1038/s41556-018-0045-z
10.1016/j.cell.2004.11.050
10.3389/fcell.2021.703629
10.1007/s11033-017-4139-7
10.3389/fonc.2018.00106
10.1136/bmjopen-2021-060436
10.1016/j.molcel.2004.10.013
10.1101/gad.1256804
10.1038/sj.onc.1208236
10.1186/s12885-020-07687-3
10.15252/embj.2020106276
10.1186/s13046-018-0947-4
10.3322/caac.21726
10.1016/j.semcancer.2019.05.012
10.1073/pnas.1521518113
10.1038/onc.2016.25
10.1073/pnas.0907705107
10.1038/s41388-021-01854-x
10.1007/s00018-009-0177-1
10.1016/j.jbiotec.2021.08.005
10.3390/ijms22041882
10.1093/nar/gkr791
10.3322/caac.21654
10.7150/jca.49067
10.1016/j.molcel.2019.04.025
10.18632/aging.202824
10.1038/ncb2152
10.3390/ijms13021886
10.1016/j.stem.2007.06.002
10.1038/s41419-020-03340-w
10.1053/j.gastro.2020.09.016
10.1158/0008-5472.CAN-18-2849
10.1186/s12935-020-01210-1
10.1001/jama.2013.279201
10.3390/cancers13092168
10.1038/s41422-018-0034-6
10.1186/s12943-019-1063-6
10.1200/JCO.2008.16.6702
10.1186/s12943-019-1128-6
10.1042/BJ20050553
10.1016/S1097-2765(03)00443-X
10.1158/0008-5472.CAN-19-4044
10.1007/s13311-019-00826-0
10.1158/0008-5472.CAN-10-1769
10.1038/nm.2157
10.1038/s41598-020-77960-9
10.1016/S1097-2765(02)00636-6
10.1101/gad.299958.117
10.1038/onc.2011.102
10.1038/369756a0
10.1101/gad.335166.119
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-022-01647-0
DatabaseName CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 20
ExternalDocumentID oai_doaj_org_article_724a2bfd3f374b5aa47c6418de8f4aec
PMC9438157
A716031450
10_1186_s12943_022_01647_0
GeographicLocations United States
China
Grand Island New York
St Louis Missouri
United States--US
Germany
GeographicLocations_xml – name: China
– name: United States
– name: Germany
– name: Grand Island New York
– name: St Louis Missouri
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014; 2021GXNSFDA075014
– fundername: ;
  grantid: 81871938; 81871938; 81871938; 81871938; 81871938; 81871938; 81871938; 81871938; 81871938
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c470t-dc1854e8d775150f91404c04fb88b706162a5e3959ee06e9058fd918ea1453c53
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:32:26 EDT 2025
Thu Aug 21 14:12:38 EDT 2025
Mon Jul 21 09:33:37 EDT 2025
Fri Jul 25 05:23:30 EDT 2025
Tue Jun 17 21:49:17 EDT 2025
Tue Jun 10 20:48:48 EDT 2025
Tue Jul 01 01:01:20 EDT 2025
Thu Apr 24 23:07:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-dc1854e8d775150f91404c04fb88b706162a5e3959ee06e9058fd918ea1453c53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-022-01647-0
PMID 36056355
PQID 2715578894
PQPubID 42702
PageCount 20
ParticipantIDs doaj_primary_oai_doaj_org_article_724a2bfd3f374b5aa47c6418de8f4aec
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9438157
proquest_miscellaneous_2709736402
proquest_journals_2715578894
gale_infotracmisc_A716031450
gale_infotracacademiconefile_A716031450
crossref_primary_10_1186_s12943_022_01647_0
crossref_citationtrail_10_1186_s12943_022_01647_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-02
PublicationDateYYYYMMDD 2022-09-02
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-02
  day: 02
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Molecular cancer
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References KH Ho (1647_CR20) 2020; 17
B Tang (1647_CR10) 2020; 19
M Feng (1647_CR31) 2018; 37
C Qiu (1647_CR30) 2020; 20
J Brugarolas (1647_CR34) 2004; 18
DC Marshall (1647_CR15) 2022; 72
YK Kim (1647_CR52) 2005; 120
L Lin (1647_CR12) 2005; 392
M Zhou (1647_CR48) 2021; 12
P Horak (1647_CR19) 2010; 107
Z Li (1647_CR29) 2021; 12
HO Jin (1647_CR35) 2011; 30
X Deng (1647_CR6) 2018; 28
L Unterholzner (1647_CR54) 2004; 16
M Xu (1647_CR50) 2019; 18
I Tirado-Hurtado (1647_CR13) 2018; 8
I Ben Sahra (1647_CR22) 2011; 71
Z Madak-Erdogan (1647_CR44) 2019; 79
J Zhou (1647_CR46) 2020; 20
Z-F Miao (1647_CR18) 2021; 160
Q Xu (1647_CR33) 2021; 13
BM Davies (1647_CR11) 2022; 12
J Kim (1647_CR42) 2011; 13
K Wang (1647_CR28) 2020; 68
C Shen (1647_CR26) 2020; 27
T Yoshida (1647_CR17) 2010; 16
T Ohnishi (1647_CR36) 2003; 12
AM Elsayed (1647_CR47) 2021; 22
H Pópulo (1647_CR41) 2012; 13
R Schwarzer (1647_CR21) 2005; 24
H Huang (1647_CR7) 2020; 80
MP DeYoung (1647_CR16) 2008; 22
P Zhang (1647_CR37) 2021; 9
HS Seol (1647_CR27) 2020; 10
H Shi (1647_CR5) 2019; 74
Y Okada-Katsuhata (1647_CR53) 2012; 40
P Nicholson (1647_CR55) 2010; 67
RL Siegel (1647_CR1) 2021; 71
J Brugarolas (1647_CR14) 2004; 18
PC Hermann (1647_CR3) 2007; 1
É Audet-Walsh (1647_CR45) 2017; 31
P Gupta (1647_CR51) 2018; 45
R Loewith (1647_CR40) 2002; 10
B Huang (1647_CR49) 2016; 35
EJ Brown (1647_CR39) 1994; 369
S Qiao (1647_CR23) 2020; 34
H Oettle (1647_CR2) 2013; 310
S Xi (1647_CR32) 2021; 40
CJ Lee (1647_CR4) 2008; 26
MK Ediriweera (1647_CR43) 2019; 59
C Zhang (1647_CR9) 2016; 113
JC Krappinger (1647_CR24) 2021; 340
1647_CR25
H Huang (1647_CR38) 2018; 20
J Lee (1647_CR8) 2021; 40
References_xml – volume: 27
  start-page: 64
  issue: 1
  year: 2020
  ident: 1647_CR26
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2020.04.009
– volume: 68
  start-page: 153191
  year: 2020
  ident: 1647_CR28
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2020.153191
– volume: 22
  start-page: 239
  year: 2008
  ident: 1647_CR16
  publication-title: Genes Dev
  doi: 10.1101/gad.1617608
– volume: 20
  start-page: 285
  year: 2018
  ident: 1647_CR38
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0045-z
– volume: 120
  start-page: 195
  year: 2005
  ident: 1647_CR52
  publication-title: Cell
  doi: 10.1016/j.cell.2004.11.050
– volume: 9
  start-page: 703629
  year: 2021
  ident: 1647_CR37
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2021.703629
– volume: 45
  start-page: 39
  year: 2018
  ident: 1647_CR51
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-017-4139-7
– volume: 8
  start-page: 106
  year: 2018
  ident: 1647_CR13
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00106
– volume: 12
  start-page: e060436
  year: 2022
  ident: 1647_CR11
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2021-060436
– volume: 16
  start-page: 587
  year: 2004
  ident: 1647_CR54
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2004.10.013
– volume: 18
  start-page: 2893
  year: 2004
  ident: 1647_CR34
  publication-title: Genes Dev
  doi: 10.1101/gad.1256804
– volume: 24
  start-page: 1138
  year: 2005
  ident: 1647_CR21
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208236
– volume: 20
  start-page: 1187
  year: 2020
  ident: 1647_CR30
  publication-title: BMC Cancer
  doi: 10.1186/s12885-020-07687-3
– volume: 40
  start-page: e106276
  year: 2021
  ident: 1647_CR8
  publication-title: EMBO J
  doi: 10.15252/embj.2020106276
– volume: 37
  start-page: 274
  year: 2018
  ident: 1647_CR31
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-018-0947-4
– volume: 72
  start-page: 353
  issue: 4
  year: 2022
  ident: 1647_CR15
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21726
– volume: 59
  start-page: 147
  year: 2019
  ident: 1647_CR43
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2019.05.012
– volume: 113
  start-page: E2047
  year: 2016
  ident: 1647_CR9
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1521518113
– volume: 35
  start-page: 4927
  year: 2016
  ident: 1647_CR49
  publication-title: Oncogene
  doi: 10.1038/onc.2016.25
– volume: 107
  start-page: 4675
  year: 2010
  ident: 1647_CR19
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0907705107
– volume: 40
  start-page: 4453
  issue: 26
  year: 2021
  ident: 1647_CR32
  publication-title: Oncogene
  doi: 10.1038/s41388-021-01854-x
– volume: 67
  start-page: 677
  year: 2010
  ident: 1647_CR55
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-009-0177-1
– volume: 340
  start-page: 75
  year: 2021
  ident: 1647_CR24
  publication-title: J Biotechnol
  doi: 10.1016/j.jbiotec.2021.08.005
– volume: 22
  start-page: 1882
  issue: 4
  year: 2021
  ident: 1647_CR47
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22041882
– volume: 40
  start-page: 1251
  year: 2012
  ident: 1647_CR53
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkr791
– volume: 71
  start-page: 7
  year: 2021
  ident: 1647_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21654
– volume: 12
  start-page: 1499
  year: 2021
  ident: 1647_CR48
  publication-title: J Cancer
  doi: 10.7150/jca.49067
– volume: 74
  start-page: 640
  year: 2019
  ident: 1647_CR5
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2019.04.025
– volume: 13
  start-page: 11315
  year: 2021
  ident: 1647_CR33
  publication-title: Aging
  doi: 10.18632/aging.202824
– volume: 13
  start-page: 132
  year: 2011
  ident: 1647_CR42
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2152
– volume: 13
  start-page: 1886
  year: 2012
  ident: 1647_CR41
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms13021886
– volume: 1
  start-page: 313
  year: 2007
  ident: 1647_CR3
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2007.06.002
– volume: 12
  start-page: 97
  year: 2021
  ident: 1647_CR29
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-03340-w
– volume: 160
  start-page: 260
  year: 2021
  ident: 1647_CR18
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.09.016
– volume: 79
  start-page: 2494
  year: 2019
  ident: 1647_CR44
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-18-2849
– volume: 20
  start-page: 134
  year: 2020
  ident: 1647_CR46
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-020-01210-1
– volume: 310
  start-page: 1473
  year: 2013
  ident: 1647_CR2
  publication-title: JAMA
  doi: 10.1001/jama.2013.279201
– ident: 1647_CR25
  doi: 10.3390/cancers13092168
– volume: 28
  start-page: 507
  year: 2018
  ident: 1647_CR6
  publication-title: Cell Res
  doi: 10.1038/s41422-018-0034-6
– volume: 18
  start-page: 135
  year: 2019
  ident: 1647_CR50
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1063-6
– volume: 26
  start-page: 2806
  year: 2008
  ident: 1647_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.16.6702
– volume: 19
  start-page: 3
  year: 2020
  ident: 1647_CR10
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1128-6
– volume: 392
  start-page: 93
  year: 2005
  ident: 1647_CR12
  publication-title: Biochem J
  doi: 10.1042/BJ20050553
– volume: 12
  start-page: 1187
  year: 2003
  ident: 1647_CR36
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(03)00443-X
– volume: 80
  start-page: 3200
  year: 2020
  ident: 1647_CR7
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-19-4044
– volume: 17
  start-page: 1212
  year: 2020
  ident: 1647_CR20
  publication-title: Neurotherapeutics
  doi: 10.1007/s13311-019-00826-0
– volume: 71
  start-page: 4366
  year: 2011
  ident: 1647_CR22
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1769
– volume: 16
  start-page: 767
  year: 2010
  ident: 1647_CR17
  publication-title: Nat Med
  doi: 10.1038/nm.2157
– volume: 10
  start-page: 21412
  year: 2020
  ident: 1647_CR27
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-77960-9
– volume: 18
  start-page: 2893
  year: 2004
  ident: 1647_CR14
  publication-title: Genes Dev
  doi: 10.1101/gad.1256804
– volume: 10
  start-page: 457
  year: 2002
  ident: 1647_CR40
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(02)00636-6
– volume: 31
  start-page: 1228
  year: 2017
  ident: 1647_CR45
  publication-title: Genes Dev
  doi: 10.1101/gad.299958.117
– volume: 30
  start-page: 3792
  year: 2011
  ident: 1647_CR35
  publication-title: Oncogene
  doi: 10.1038/onc.2011.102
– volume: 369
  start-page: 756
  year: 1994
  ident: 1647_CR39
  publication-title: Nature
  doi: 10.1038/369756a0
– volume: 34
  start-page: 751
  year: 2020
  ident: 1647_CR23
  publication-title: Genes Dev
  doi: 10.1101/gad.335166.119
SSID ssj0017874
Score 2.575862
Snippet Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most...
Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors...
Abstract Background Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms ALKBH5
Animal models
Antibodies
Binding sites
Bioinformatics
Cancer
Care and treatment
Chemoresistance
Chemosensitivity
Chemotherapy
DDIT4-AS1
DNA damage
Drug resistance
Flow cytometry
Gemcitabine
Growth factors
HuR protein
Hypoxia
Immunoprecipitation
Medical prognosis
Methyltransferases
Molecular modelling
mRNA stability
N6-methyladenosine
Pancreatic cancer
Patients
Phosphorylation
Prognosis
Proteins
RNA
RNA sequencing
Scientific equipment and supplies industry
Stemness
TOR protein
Tumors
UPF1
Xenografts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kQfEiuipGV2lB8CBh86h-HWddl_GxCjoLe2vSj-iCkxkmM8j8HP-pVUlm2CjoxWu6k3TyVXVVdVd_xdgLl0NAswMphl4YoAThUlM6mXpHBGZeQfC0Dnn-UU4v4N2luLxW6otywnp64P7HHasCqsLVoaxLBU5UFSgvIdch6hqq6Gn2RZu3C6aG_QMUQ9gdkdHyuEWrBrRfSWkIElSajcxQx9b_55z8e57kNcNzdpfdGTxGPulHeo_diM0hu9nXkNweslvnw-74ffYTMedzOeEhUmHoLTrGkU8-vD-ZirQ7IYLeJd8sV335eQSEL2p-evp2BunkS87n1VVDCwUtxxmidyY99yQVK050zzQp8qoJvN0su_TZ2HKEfL5oKQm-r0LB3ZbTUQla6G2-8jUNaPbpM6fCxz-q7QN2cfZm9nqaDiUYUg8qW6fBoz2HqINS6PhktSE2Hp9B7bR2Cn0BWVQilkaYGDMZTSZ0HUyuY5WDKL0oH7KDZtHER4ybvM5i6TPpEQGEwylvoIZaRnxWyHTC8h0i1g_85FQm47vt4hQtbY-iRRRth6LNEvZqf8-yZ-f4a-8TAnrfk5i1uwsob3aQN_sveUvYSxITS_qPw_PVcIwBP5KYtOxEdYW7QeDrjkY9UW_9uHknaHaYN1pbKPTvlNYGEvZ830x3Ui5cExcb6kMUSxID_4SpkYCOvmzc0lx967jDDVG6CfX4f_yKJ-x20amUQc06Ygfr1SY-RRdt7Z512vgL00I5lw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgCMQLggGiMJCRkHhA0ZLm2I6fUMeYymUgQSftzYovGZNoUppWqD-Hf8o5TloISHuNnZu-43Pz8XcYe2Ez8Gh2IMHQCwMUL2yicysTZ4nAzCnwjvKQp5_k9Azen4vzPuHW9mWVW50YFbVvHOXID8cKLR_GaxpeL34k1DWKdlf7FhrX2Q2iLqOSLnW-C7gyFEbYHpQp5GGLtg1o15KKESSoJB0Yo8jZ_79m_rda8i_zc3KX3en9Rj7pgL7HroV6n93sOklu9tmt036P_D77hcjzuZxwH6g99Abd48AnHz8cTUUSz4mgj8nXi2XXhB5h4U3Fj4_fzSCZfM34vLysKV3QctQTnUvpuCPZWHIifSbVyMva83a9iEW0oeUI_LxpqRS-60XB7YbTgQlK99YXfEUfNPv8hVP745_l5gE7O3k7ezNN-kYMiQOVrhLv0KpDKLxS6P6klSZOHpdCZYvCKvQI5LgUIddCh5DKoFNRVF5nRSgzELkT-UO2Vzd1eMS4zqo05C6VDhFAOKxyGiqoZMBn-bQYsWyLiHE9Szk1y_huYrRSSNOhaBBFE1E06Yi92t2z6Dg6rpx9REDvZhK_drzQLC9Mv1yNGkM5tpXPq1yBFWUJyknICh-KCsrgRuwliYkhLYCf58r-MAP-JPFpmYmK7btB4OsOBjNx9brh8FbQTK89WvNH1kfs-W6Y7qSKuDo0a5pDREsSw_8RUwMBHfzZcKS-_BYZxDURuwn1-OqXP2G3x3GxaFwzB2xvtVyHp-iCreyzuM5-Ayr8MAA
  priority: 102
  providerName: ProQuest
Title The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway
URI https://www.proquest.com/docview/2715578894
https://www.proquest.com/docview/2709736402
https://pubmed.ncbi.nlm.nih.gov/PMC9438157
https://doaj.org/article/724a2bfd3f374b5aa47c6418de8f4aec
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGJqa9IBggCqMyEhIPKJCPi-08INSyTeWjA41W6puVOM6YtKalaQX9c_hPuXPSQmDigdfYztfd-e7s8-_H2NMsgBzdDniYemGCkseZl0SZ8ExGAGZGQm5oHXJ4JgZjeDeJJztsQ3fU_MDq2tSO-KTGi6sX37-uX6PBv3IGr8TLCn0W0G4kFRkIkB6m8HvomSQZ6hB-7SqgcsLm4My14w7YfoTxPTnhlp9ycP5_T9p_FlL-5plOb7NbTUjJe7UO3GE7tjxkN2uSyfUh2x822-d32Q9UCj4VPZ5bYo5eY-Rsee_D-_4g9twREgw_-Wq-qPnpUWJ8VvDj47cj8HqfAz5NL0taSag4TiF1tGm4IbVZcMKDplmTp2XOq9Xc1dfaiqNOTGcVVcnXNBU8W3M6S0ErweUFX9ILjT6ec2JG_pau77Hx6cnozcBrOBo8A9JferlBhw9W5VJiZOQXCcH1GB-KTKlMYrAgwjS2URIn1vrCJn6sijwJlE0DiCMTR_fZbjkr7QPGk6DwbWR8YVAYKJlMmgQKKITFe-W-6rBgIxFtGgBz4tG40i6RUULXAtUoUO0Eqv0Oe74dM6_hO_7Zu0-C3vYk6G13Yba40I0laxlCGmZFHhWRhCxOU5BGQKByqwpIremwZ6QmmlQWX8-kzTkH_EiC2tI96Zi9IcbHHbV6omGbdvNG0fTGLnQoMQCUSiXQYU-2zTSSiuVKO1tRH8JgEuCHHSZbCtr6snZLefnFgYsnhPkWy4f_PfIROwidSSVoWUdsd7lY2ccYuC2zLrshJ7LL9vonZ5_Ou275o-ss9Cdp4UPV
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqVjwuCAqIhQJGAnFAUZ3EsZMDQrtsq132ASpbqTc3sZ1SiU2Wza6q_Tn8AX4jM3ksBKTeeo2dl-abGY89Mx8hrxOXG3A73IHQCwIUEyRO5CfC0Qk2MNOSG437kJOpGJzyT2fB2Q751dTCYFplYxNLQ21yjXvkh54EzwfxWsQ_LH44yBqFp6sNhUYFi5HdXEHIVrwf9kG-bzzv-Gj2ceDUrAKO5pKtHKPBRXEbGinBl7M0wgYzmvE0CcNEgnsTXhxYPwoia5mwEQvC1ERuaGOXB75Glggw-Xvch1Bml-z1jqZfTrbnFgB_3pTmhOKwAG_K8ZwU0x8Elw5rub-SJeB_X_BvfuZfDu_4PrlXr1Rpt4LWA7Jjs31yq-Ku3OyT25P6VP4h-QlYo3PRpcYiIfUGFuSWdsej3iBwysoUWNXS9WJZ0d4DEGie0n5_OONO96tL5_FlhhsUBQXLVC1iNdWIxiXFNtNojGmcGVqsF2Xari0oQG2eF5h8X7Ff0GRDsUQDN5izC7rCD5p9PqFIuHwVbx6R0xsR0mOym-WZfUJo5KbM-poJDRIAcSRSRzzlqbDwLMPCDnEbiShd90VHeo7vqoyPQqEqKSqQoiqlqFiHvNves6i6glw7u4eC3s7Ejt7lhXx5oWoDoaTHYy9JjZ_6kidBHHOpBXdDY8OUx1Z3yFuEiUK7A5-n47p8An4SO3ipriwJw3kArztozQR7odvDDdBUba8K9Ue7OuTVdhjvxBy8zOZrnIOtnQRnXofIFkBbf9YeyS6_lT3LI2wlF8in17_8JbkzmE3Gajycjp6Ru16pOBHozwHZXS3X9jksAFfJi1rrKDm_aUX_DaqLbEs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+m6A+demethylase+ALKBH5-mediated+upregulation+of+DDIT4-AS1+maintains+pancreatic+cancer+stemness+and+suppresses+chemosensitivity+by+activating+the+mTOR+pathway&rft.jtitle=Molecular+cancer&rft.au=Zhang%2C+Yi&rft.au=Liu%2C+Xiaomeng&rft.au=Wang%2C+Yan&rft.au=Lai%2C+Shihui&rft.date=2022-09-02&rft.pub=BioMed+Central&rft.eissn=1476-4598&rft.volume=21&rft_id=info:doi/10.1186%2Fs12943-022-01647-0&rft_id=info%3Apmid%2F36056355&rft.externalDocID=PMC9438157
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon